<DOC>
	<DOCNO>NCT01237678</DOCNO>
	<brief_summary>The purpose study test safety efficacy combination treatment ( IMGN901 , carboplatin etoposide ) patient solid tumor extensive stage small cell lung cancer .</brief_summary>
	<brief_title>A Study Test Safety Efficacy IMGN901 Combination With Carboplatin/Etoposide Patients With Advanced Solid Tumors Extensive Stage Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Patients must 18 year old Patients must diagnose smallcell lung cancer ( SCLC ) extensive disease ECOG performance status 0 , 1 , 2 No prior systemic chemotherapy treatment SCLC Pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Immunogen</keyword>
	<keyword>Lung</keyword>
	<keyword>Small Cell Lung Cancer</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>ADC</keyword>
</DOC>